?
Division of Radiobiology
Research
The Division is well equipped for state-of-the-art research, and our research is specifically directed toward:
- small molecule inhibitor-based targeted cancer therapy;
- radionuclide-based cancer therapy;
- modeling tumour and normal tissue responses from the characteristics of the distributions of chemotherapeutic drugs and radiopharmaceuticals among cells;
- macro- and micro-dosimetry of incorporated radiochemicals: impact of radionuclide distribution on biologic response;
- radiotherapy gaps: dosimetry, normal tissue toxicity and tumour control;
- chemotherapeutic drugs and specific inhibitors as an adjuvant to external beam therapy: efficacy versus adverse toxicity;
- low-to-intermediate frequency electromagnetic fields as an adjuvant to external beam therapy: efficacy versus adverse toxicity;
- small molecule inhibitors as radiomodulators;
- radiosensitisers and radioprotectors; and
- cancer biomarkers.
